Compras y ventas de directivos de Amgen (AMGN)
Qué compran y venden los consejeros y directivos del S&P 500 en sus propias empresas, tal cual lo presentan en los Formularios 4 de la SEC (2 días hábiles de plazo): cada fila con su código oficial y sin filtrar nada.
Las compras en mercado abierto (código P) son la señal rara, en verde; las ventas (código S) son frecuentes y muchas van programadas (10b5-1). La tabla II (derivados) no se incluye: sus precios son de ejercicio, no de mercado. Guía: compras de directivos.
| Fecha | Ticker | Directivo | Cargo | Acciones | Precio | Importe | % posición | Tipo / documento |
|---|
Descargar estas transacciones en CSV Sin cuenta y sin registro. Los datos son públicos: salen de los Formularios 4 de la SEC.
Compras y ventas de directivos de Amgen Inc. (AMGN): ninguna compra y 10 ventas
106 transacciones de la tabla I del Formulario 4 declaradas ante la SEC por directivos de Amgen Inc. entre el 2025-11-07 y el 2026-08-13 (histórico de 15 meses): 0 compras y 10 ventas en mercado abierto, y 96 transacciones con otros códigos del Formulario 4, desglosados uno a uno más abajo. La mayor operación en mercado abierto es una venta de $20,8M de Santos Esteban el 2026-02-26.
Compras y ventas de directivos de Amgen en los últimos 12 meses
Entre el 21 oct 2025 y el 20 oct 2026, los directivos de Amgen declararon 10 ventas por $29,3M en mercado abierto, y ninguna compra.
Quien más vendió fue Santos Esteban (EVP, Operations): $20,8M en 1 venta, de 6 vendedores distintos.
La mayor operación del período fue una venta de $20,8M el 26 feb 2026, de Santos Esteban (EVP, Operations). Formulario 4 en sec.gov (0000318154-26-000012).
Ninguna de las 10 ventas lleva en el Formulario 4 la marca de plan 10b5-1 (las ventas programadas con meses de antelación).
En los tres últimos meses hay 4 ventas, frente a 1 en los tres anteriores. La última venta es del 13 ago 2026.
Frente a su sector (Salud, 59 empresas con página de directivos en esta web), en las mismas fechas la mediana es de 9 ventas y 0 compras en mercado abierto. Amgen tiene más ventas que 31 de las otras 58, es la 23.ª de 59 por dinero neto vendido, y 19 de las 59 tienen al menos una compra.
Las 20 operaciones más importantes
Como AMGN no tiene compras en mercado abierto, la tabla empieza por sus ventas, de mayor a menor importe. El histórico completo está en la herramienta de arriba, ya buscado.
Ver las 106 operaciones de AMGN en el histórico completo →
| Operación | Declarada | Directivo | Cargo | Importe | Código | Documento |
|---|---|---|---|---|---|---|
| 2026-02-26 | 2026-03-02 | Santos Esteban | EVP, Operations | $20,8M | S — Venta en mercado abierto3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2 The price reported is an average price of $379.1173 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer F3 These shares include 624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2025-11-12 | 2025-11-13 | Gordon Murdo | EVP, Global Commercial Ops | $2,3M | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported is an average price. The prices ranged from $336.7301 to $337.0500 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 These shares include 647 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-08-06 | 2026-08-07 | Miller Derek | SVP, Human Resources | $1,6M | S — Venta en mercado abierto3 notas del Formulario 4 (texto original de la SEC, en inglés)F1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2 The price reported is an average price of $402.5444 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. F3 These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-08-06 | 2026-08-07 | Grygiel Nancy A. | SVP & CCO | $1,2M | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2 These shares include 68 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2025-11-20 | 2025-11-21 | Grygiel Nancy A. | SVP & CCO | $1,1M | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-08-11 | 2026-08-13 | Khosla Rachna | SVP, Business Development | $825k | S — Venta en mercado abierto | SEC |
| 2026-08-13 | 2026-08-13 | Khosla Rachna | SVP, Business Development | $521k | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options. F2 These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-05-04 | 2026-05-05 | Grygiel Nancy A. | SVP & CCO | $400k | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported is an average price of $323.7272 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer F2 These shares include 72 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-02-19 | 2026-02-20 | Busch Matthew C. | VP, Finance & CAO | $376k | S — Venta en mercado abiertoNota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares include 60 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2025-11-12 | 2025-11-13 | Khosla Rachna | SVP, Business Development | $299k | S — Venta en mercado abierto2 notas del Formulario 4 (texto original de la SEC, en inglés)F1 The price reported is an average price. The prices ranged from $336.2219 to $336.30 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 These shares include 93 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-04 | 2026-03-06 | Bradway Robert A | Chairman, CEO and President | $32,0M | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F2 These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-04 | 2026-03-06 | Bradway Robert A | Chairman, CEO and President | $18,7M | M — Ejercicio de opcionesNota del Formulario 4 (texto original de la SEC, en inglés)F1 Non-market exercise of a total of 119,872 stock options expiring May 3, 2026 wherein 84,285 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person. | SEC |
| 2026-02-26 | 2026-03-02 | Santos Esteban | EVP, Operations | $9,3M | M — Ejercicio de opciones | SEC |
| 2026-03-16 | 2026-03-18 | Bradway Robert A | Chairman, CEO and President | $7,8M | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares include 2,696 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Gordon Murdo | EVP, Global Commercial Ops | $2,5M | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares include 825 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Reese David M | EVP & Chief Technology Officer | $2,2M | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares include 744 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Griffith Peter H. | EVP & CFO | $2,1M | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares include 756 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Santos Esteban | EVP, Operations | $2,1M | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares include 696 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-03-16 | 2026-03-18 | Graham Jonathan P | EVP & Gen. Counsel & Sec. | $2,0M | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares include 659 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
| 2026-05-02 | 2026-05-05 | Bradway Robert A | Chairman, CEO and President | $1,7M | F — Retención fiscal (acciones entregadas por impuestos)Nota del Formulario 4 (texto original de la SEC, en inglés)F1 These shares include 1,624 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. | SEC |
El saldo del período: cuánto dinero entra y cuánto sale
En los Formularios 4 presentados entre el 7 nov 2025 y el 13 ago 2026 no consta ni una compra en mercado abierto de Amgen Inc.: 10 ventas por $29,3M y cero dólares comprados.
Solo cuentan los códigos P y S, donde el directivo pone o saca su propio dinero. Que el saldo de Amgen Inc. salga vendedor es lo habitual en el S&P 500, donde buena parte del sueldo se cobra en acciones. No es una recomendación de comprar ni de vender: es lo que se declaró.
Todas las transacciones, código por código
| Código | Qué significa | Operaciones | Importe declarado |
|---|---|---|---|
| F | Retención fiscal (acciones entregadas por impuestos) | 46 | $60,8M |
| A | Adjudicación o premio de acciones | 42 | $0 |
| S | Venta en mercado abierto | 10 | $29,3M |
| M | Ejercicio de opciones | 6 | $29,9M |
| G | Regalo o donación | 2 | $0 |
| Total | Todo lo declarado en el período | 106 | $120,1M |
44 de las 106 filas no traen un importe utilizable en el Formulario 4: cuentan como operación y suman $0. Las etiquetas son las del índice de códigos de la SEC.
Quién ha operado
En los 15 meses del histórico han declarado operaciones de Amgen Inc. 22 personas o entidades distintas. De ellas, ninguna compró en mercado abierto y 6 vendieron. Se cuentan por su CIK, el número fijo que la SEC da a cada declarante, y no por el nombre, que cada uno escribe a su manera.
De los 6 que vendieron en mercado abierto (10 ventas en total), los tres que más vendieron suman $25,7M de los $29,3M: el 88% del dinero en tres personas.
| Declarante | Cargo | Transacciones | Comprado (nº) | Vendido (nº) | Última declarada |
|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations | 8 | — | $20,8M (1) | 2026-05-11 |
| Grygiel Nancy A. | SVP & CCO | 11 | — | $2,7M (3) | 2026-08-07 |
| Gordon Murdo | EVP, Global Commercial Ops | 7 | — | $2,3M (1) | 2026-05-11 |
| Khosla Rachna | SVP, Business Development | 11 | — | $1,6M (3) | 2026-08-13 |
| Miller Derek | SVP, Human Resources | 8 | — | $1,6M (1) | 2026-08-07 |
| Busch Matthew C. | VP, Finance & CAO | 9 | — | $376k (1) | 2026-08-12 |
| Bradway Robert A | Chairman, CEO and President | 8 | — | — | 2026-05-11 |
| Reese David M | EVP & Chief Technology Officer | 8 | — | — | 2026-05-11 |
Se enseñan los 8 que más dinero movieron, de 22. Los demás están en el histórico completo, que se abre con el enlace de arriba. El nombre lleva a todas sus operaciones, en cualquier empresa. «Transacciones» cuenta cualquier código; el dinero, solo mercado abierto. Cargo: el de su última declaración.
Mes a mes
Por el mes en que se operó, no en el que se presentó el formulario; los meses sin operaciones van a cero. El mes con más movimiento fue ago 2026: 0 compras y 4 ventas, por $4,1M. 11 de los 15 meses no tienen ninguna.
| Mes | Compras | Importe | Ventas | Importe |
|---|---|---|---|---|
| ago 2025 | 0 | $0 | 0 | $0 |
| sept 2025 | 0 | $0 | 0 | $0 |
| oct 2025 | 0 | $0 | 0 | $0 |
| nov 2025 | 0 | $0 | 3 | $3,7M |
| dic 2025 | 0 | $0 | 0 | $0 |
| ene 2026 | 0 | $0 | 0 | $0 |
| feb 2026 | 0 | $0 | 2 | $21,1M |
| mar 2026 | 0 | $0 | 0 | $0 |
| abr 2026 | 0 | $0 | 0 | $0 |
| may 2026 | 0 | $0 | 1 | $400k |
| jun 2026 | 0 | $0 | 0 | $0 |
| jul 2026 | 0 | $0 | 0 | $0 |
| ago 2026 | 0 | $0 | 4 | $4,1M |
| sept 2026 | 0 | $0 | 0 | $0 |
| oct 2026 | 0 | $0 | 0 | $0 |
El último mes puede ir incompleto: el Formulario 4 se presenta hasta dos días hábiles después. La tabla no dice si el patrón es bueno o malo; dice cuándo pasó.
Ficha de análisis de Amgen Inc. (AMGN) →
Otras empresas de Salud con operaciones de directivos
Están las 500 en el índice de la sección →
Qué directivos están comprando acciones de su propia empresa →
Cómo leer estos datos
Ninguna de las 10 ventas de la tabla va marcada como programada (plan 10b5-1), la venta que se firma con meses de antelación y se ejecuta sola. Amgen no tiene ninguna compra en mercado abierto (código P) en el histórico, que es lo más común en el S&P 500: los directivos ya cobran en acciones. La última presentación es del 13 ago 2026, y el Formulario 4 llega hasta dos días hábiles después de operar.
18 de las 20 filas de la tabla llevan notas al pie del propio Formulario 4, plegadas en la columna del código y copiadas tal cual, en inglés; una fila sin nota es que el formulario no la trae.
Guía: Compras de directivos · todas las guías
Lo que hay detrás de estas operaciones
Los conceptos de esta página, explicados desde cero en la Academia. Gratis y sin cuenta.
- Qué dice y qué NO dice la hipótesis de eficienciaSi la compra de un directivo es pública y cualquiera puede leerla, ¿queda información dentro? Es la pregunta exacta que trae a esta página.
- Quién mueve realmente el mercado: los tipos de inversoresQuién hay al otro lado de cada orden, y qué sitio ocupan entre ellos los directivos de la propia empresa.
- Oferta, demanda y el precio: por qué sube y baja constantementeCómo acaba una noticia metida en el precio, y por qué la reacción a una venta declarada rara vez es la que uno esperaría.
Fuente: SEC EDGAR Formulario 4. Esto es una lista de hechos públicos, no asesoramiento financiero ni una recomendación de compra o venta.